Compare Stocks

→ The asset beating inflation by 4x (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNA Allena Pharmaceuticals		$0.07	$0.06 ▼ $1.17	$37K	1.13	15.69 million shs	96,558 shs
BVXV BiondVax Pharmaceuticals		$1.36	$1.25 ▼ $11.80	$2.54M	2.37	127,289 shs	23,000 shs
ENTX Entera Bio	$2.16 +3.3%	$1.77	$0.52 ▼ $3.35	$62.21M	1.63	209,451 shs	235,448 shs
OTLK Outlook Therapeutics	$8.60 +1.2%	$8.56	$4.00 ▼ $40.60	$111.89M	0.28	505,061 shs	101,285 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNA Allena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BVXV BiondVax Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-28.04%
ENTX Entera Bio	+4.50%	+4.50%	+12.37%	+149.11%	+137.53%
OTLK Outlook Therapeutics	0.00%	+3.79%	-12.37%	+16.69%	-62.05%

Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning (Ad)

Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.

GET THE FREE GUIDE

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	1.2038 of 5 stars	3.5	3.0	0.0	0.0	1.9	0.0	0.0
OTLK Outlook Therapeutics	2.6261 of 5 stars	3.4	4.0	0.0	0.0	2.3	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A
ENTX Entera Bio	3.00	Buy	$10.00	362.96% Upside
OTLK Outlook Therapeutics	2.88	Moderate Buy	$46.43	439.83% Upside

Current Analyst Ratings

Latest OTLK, ENTX, BVXV, and ALNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2024	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/27/2024	OTLK Outlook Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
3/25/2024	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00
2/16/2024	OTLK Outlook Therapeutics	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
2/15/2024	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00

(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	$0.23 per share	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	($3.81) per share	N/A
ENTX Entera Bio	$130K	478.52	N/A	N/A	$0.36 per share	6.00
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.11) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNA Allena Pharmaceuticals	-$48.66M	N/A	0.00	N/A	N/A	N/A	-287.46%	-146.58%	N/A
BVXV BiondVax Pharmaceuticals	-$5.80M	-$2.55	N/A	N/A	N/A	N/A	-346.36%	-29.52%	N/A
ENTX Entera Bio	-$8.89M	-$0.31	N/A	N/A	N/A	N/A	-101.78%	-83.90%	5/3/2024 (Estimated)
OTLK Outlook Therapeutics	-$58.98M	-$4.00	N/A	N/A	N/A	N/A	-3,741.39%	-132.37%	5/20/2024 (Estimated)

Latest OTLK, ENTX, BVXV, and ALNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/8/2024	Q4 2023	ENTX Entera Bio	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A
2/14/2024	Q1 2024	OTLK Outlook Therapeutics	-$1.00	-$0.80	+$0.20	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNA Allena Pharmaceuticals	N/A	1.58	1.58
BVXV BiondVax Pharmaceuticals	N/A	4.12	4.12
ENTX Entera Bio	N/A	10.32	10.32
OTLK Outlook Therapeutics	N/A	0.44	0.44

Ownership

Institutional Ownership

Company	Institutional Ownership
ALNA Allena Pharmaceuticals	7.33%
BVXV BiondVax Pharmaceuticals	11.83%
ENTX Entera Bio	14.11%
OTLK Outlook Therapeutics	11.20%

Insider Ownership

Company	Insider Ownership
ALNA Allena Pharmaceuticals	3.70%
BVXV BiondVax Pharmaceuticals	6.03%
ENTX Entera Bio	8.90%
OTLK Outlook Therapeutics	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNA Allena Pharmaceuticals	35	122.08 million	117.57 million	Not Optionable
BVXV BiondVax Pharmaceuticals	33	1.87 million	1.76 million	Not Optionable
ENTX Entera Bio	17	28.80 million	26.24 million	Optionable
OTLK Outlook Therapeutics	24	13.01 million	12.32 million	Optionable

OTLK, ENTX, BVXV, and ALNA Headlines

Source	Headline
	Global $320 Billion Aviation Fuel Market Outlook, 2024-2029: Emission Reduction Initiatives, Rising Air Freight Demand, Emerging Markets finance.yahoo.com - May 3 at 3:15 AM
	How to fix Microsoft Outlook msn.com - May 3 at 3:15 AM
	Outlook Therapeutics® to Present at the Retina World Congress 2024 globenewswire.com - May 2 at 9:05 AM
	Economic Outlook Conference to be held Monday on CWU campus cwu.edu - May 1 at 8:40 PM
	CEOs and Investors Navigate Shifting Economic Terrain: Outlook Revealed in EY CEO Pulse Survey news.europawire.eu - May 1 at 3:40 PM
	Outlook News Wrap, May 1: 100 Schools In Delhi Get Bomb Threat, Heatwave Alert Issued Amid 47 Deg Temperature, Split In Godrej & More outlookindia.com - May 1 at 9:56 AM
	Q1 2024 CA Auto Outlook: Tesla registrations drop; Sales slip 7.8% YTD ivpressonline.com - April 30 at 2:18 PM
	Natural Gas News: Freeport LNG Resumption Brightens Outlook fxempire.com - April 29 at 1:15 PM
	Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase globenewswire.com - April 29 at 9:00 AM
	These 5 programs are way better than Microsoft Outlook msn.com - April 29 at 8:15 AM
	HCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 Outlook usnews.com - April 29 at 8:15 AM
	Short Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Declines By 15.0% americanbankingnews.com - April 29 at 2:18 AM
	Best's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation Council finance.yahoo.com - April 29 at 1:28 AM
	Bulgaria's Eurozone Aspirations: Fitch Ratings Affirms Positive Outlook novinite.com - April 27 at 7:18 AM
	Outlook Magazine's Reporters Guarantee: Editor's Exclusive outlookindia.com - April 27 at 2:18 AM
	Outlook man accused of dragging girlfriend with his car yakimaherald.com - April 27 at 2:18 AM
	Global Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036 finance.yahoo.com - April 26 at 4:17 PM
	How to Use Copilot in Outlook msn.com - April 26 at 4:17 PM
	Outlook's Next Issue: Inside The Election Cauldron outlookindia.com - April 26 at 4:17 PM
	Media advisory - OECD Economic Outlook 2024 oecd.org - April 26 at 6:16 AM
	Best's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positive finance.yahoo.com - April 22 at 1:21 PM
	USD/JPY Forecast: BoJ’s Rate Hike Talks and the Yen’s Outlook fxempire.com - April 22 at 1:21 PM
	WGA Releases New Housing Finance Outlook markets.businessinsider.com - April 22 at 1:21 PM
	Outlook Money’s Tushar Ghosh elevated to Publishing Director pitchonnet.com - April 22 at 1:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Allena Pharmaceuticals

NASDAQ:ALNA

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

BiondVax Pharmaceuticals

NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Entera Bio

NASDAQ:ENTX

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Outlook Therapeutics

NASDAQ:OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial